STOCKHOLDERS’ EQUITY (Tables)
|
6 Months Ended |
Sep. 30, 2026 |
|---|
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |
|
| SCHEDULE OF RESTRICTED STOCK AWARDS |
A
summary of the Company’s restricted stock unit awards for the six months ended September 30, 2026 is as follows:
SCHEDULE OF RESTRICTED STOCK AWARDS
| | |
Number Of Shares | | |
Weighted
Average Grant
Date Fair Value | |
| | |
| | |
| |
| Unvested as of March 31, 2026 | |
| 475 | | |
$ | 2,588.20 | |
| Granted | |
| - | | |
| - | |
| Vested | |
| - | | |
| - | |
| Forfeited | |
| - | | |
| - | |
| Unvested as of September 30, 2026 | |
| 475 | | |
$ | 2,588.20 | |
|
| SCHEDULE OF FAIR VALUE OF OPTION |
The
following was utilized to calculate the fair value of options on the date of grant:
SCHEDULE
OF FAIR VALUE OF OPTION
| |
|
September
30, 2026 |
|
|
September
30, 2025 |
|
| Risk-free
interest rate |
|
|
4.26 |
% |
|
|
3.7
– 4.2 |
% |
| Expected
volatility (Beyond Air) |
|
|
103.9 |
% |
|
|
91.6
– 96.3 |
% |
| Expected
volatility (Beyond Cancer) |
|
|
N/A |
% |
|
|
N/A |
% |
| Expected
volatility (NeuroNOS) |
|
|
N/A |
% |
|
|
95 |
% |
| Dividend
yield |
|
|
0 |
% |
|
|
0 |
% |
| Expected
terms (in years) |
|
|
6.25 |
|
|
|
6.25 |
|
|
| SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE |
The
following summarizes the components of stock-based compensation expense which included stock options and restricted stock units for the
three and six months ended September 30, 2026 and September 30, 2025 (in thousands):
SCHEDULE
OF STOCK-BASED COMPENSATION EXPENSE
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
Three Months Ended | | |
Six Months Ended | |
| | |
September 30, | | |
September 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| Research and development | |
$ | 123 | | |
$ | 301 | | |
$ | 233 | | |
$ | 601 | |
| General and administrative | |
| 303 | | |
| 1,474 | | |
| 1,229 | | |
| 2,751 | |
| Total stock-based compensation expense | |
$ | 426 | | |
$ | 1,775 | | |
$ | 1,462 | | |
$ | 3,352 | |
|
| SUMMARY OF OUTSTANDING WARRANTS |
A
summary of the Company’s outstanding warrants as of September 30, 2026 is as follows:
SUMMARY
OF OUTSTANDING WARRANTS
| Warrant Holders | |
Number of Warrants | | |
Exercise Price | | |
Intrinsic Value (in thousands) | | |
Date of Expiration |
| | |
| | |
| | |
| | |
|
| NitricGen agreement | |
| 200 | | |
$ | 2,760.00 | | |
$ | - | | |
January 2028 |
| Avenue agreement | |
| 585 | | |
$ | 151.72 | | |
| - | | |
June 2028 |
| March 2024 raise | |
| 24,108 | | |
$ | 900.00 | | |
| - | | |
March 2027 |
| Avenue extension agreement | |
| 250 | | |
$ | 512.00 | | |
| - | | |
June 2029 |
| September 2024 equity offering | |
| 27,764 | | |
$ | 151.72 | | |
| - | | |
September 2029 |
| September 2024 debt instrument | |
| 63,542 | | |
$ | 39.00 | | |
| - | | |
September 2029 / November 2030 |
| September 2025 inducement | |
| 35,982 | | |
$ | 44.20 | | |
| - | | |
September 2030 |
| January 2026 equity offering | |
| 196,542 | | |
$ | 22.94 | | |
| - | | |
January 2031 |
| July 2026 equity offering (Series A) | |
| 1,805,846 | | |
$ | 5.51 | | |
| - | | |
July
2027 (1) |
| July 2026 equity offering (Series B) | |
| 1,805,846 | | |
$ | 5.51 | | |
| - | | |
July 2031 |
| Subtotal | |
| 3,960,665 | | |
$ | 13.93 | | |
$ | - | | |
|
| | |
| | | |
| | | |
| | | |
|
| Pre-funded warrants (Sep-2024 offering) | |
| 11,002 | | |
$ | 0.040 | | |
$ | 30 | | |
September 2029 |
| Pre-funded warrants (Jul-2026 offering) | |
| 1,202,392 | | |
$ | 0.0001 | | |
$ | 3,318 | | |
N/A |
| Total | |
| 5,174,059 | | |
$ | 10.66 | | |
$ | 3,348 | | |
|
| (1) |
The
July 2026 equity offering (Series A) warrants will expire on the earlier of (i) the first anniversary of their issuance or (ii) the
date that is 45 days following approval by the U.S. Food and Drug Administration of the Company’s pending premarket approval
supplement for LungFit® PH II. |
|
| 2013 Beyond Air Equity Incentive Plan [Member] |
|
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |
|
| SCHEDULE OF OPTION ACTIVITY FOR NEURONOS |
A
summary of the change in stock options for the six months ended September 30, 2026 is as follows:
SCHEDULE OF OPTION ACTIVITY
| |
Number of Options | | |
Weighted Average Exercise Price of Options | | |
Weighted Average Remaining Contractual Life of Options | | |
Aggregate Intrinsic Value (in thousands) | |
| | |
| | |
| | |
| | |
| |
| Options outstanding as of March 31, 2026 | |
| 37,966 | | |
$ | 36.42 | | |
| 7.2 | | |
$ | - | |
| Granted | |
| 575 | | |
| 8.92 | | |
| - | | |
| - | |
| Exercised | |
| - | | |
| - | | |
| - | | |
| - | |
| Forfeited | |
| (919 | ) | |
| 21.85 | | |
| - | | |
| - | |
| Outstanding as of September 30, 2026 | |
| 37,622 | | |
$ | 36.35 | | |
| 6.7 | | |
$ | - | |
| Exercisable as of September 30, 2026 | |
| 24,777 | | |
$ | 39.00 | | |
| 5.7 | | |
$ | - | |
|
| 2021 Beyond Cancer Ltd Equity Incentive Plan [Member] |
|
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |
|
| SCHEDULE OF OPTION ACTIVITY FOR NEURONOS |
A
summary of the change in stock options for Beyond Cancer for the six months ended September 30, 2026 is as follows:
SCHEDULE
OF OPTION ACTIVITY FOR BEYOND CANCER
| | |
Number of Options | | |
Weighted Average Exercise Price of Options | | |
Weighted Average Remaining Contractual Life of Options | | |
Aggregate Intrinsic Value (thousands) | |
| | |
| | |
| | |
| | |
| |
| Options outstanding as of March 31, 2026 | |
| 2,254,500 | | |
$ | 5.50 | | |
| 6.2 | | |
$ | - | |
| Granted | |
| - | | |
| - | | |
| - | | |
| - | |
| Exercised | |
| - | | |
| - | | |
| - | | |
| - | |
| Forfeited | |
| (25,750 | ) | |
| 5.50 | | |
| - | | |
| - | |
| Outstanding as of September 30, 2026 | |
| 2,228,750 | | |
$ | 5.50 | | |
| 5.7 | | |
$ | - | |
| Exercisable as of September 30, 2026 | |
| 2,100,000 | | |
$ | 5.50 | | |
| 5.7 | | |
$ | - | |
|
| 2023 Neuro Nos Ltd Equity Incentive Plan [Member] |
|
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |
|
| SCHEDULE OF OPTION ACTIVITY FOR NEURONOS |
A
summary of the change in stock options for NeuroNOS for the six months ended September 30, 2026 is as follows:
SCHEDULE
OF OPTION ACTIVITY FOR NEURONOS
| | |
Number of Options | | |
Weighted Average Exercise Price of Options | | |
Weighted Average Remaining Contractual Life of Options | | |
Aggregate Intrinsic Value (thousands) | |
| | |
| | |
| | |
| | |
| |
| Options outstanding as of March 31, 2026 | |
| 1,259,329 | | |
$ | 0.24 | | |
| 8.1 | | |
$ | 3,477 | |
| Granted | |
| - | | |
| - | | |
| - | | |
| - | |
| Exercised | |
| - | | |
| - | | |
| - | | |
| - | |
| Forfeited | |
| (478 | ) | |
| 3.00 | | |
| - | | |
| - | |
| Outstanding as of September 30, 2026 | |
| 1,258,851 | | |
$ | 0.24 | | |
| 7.6 | | |
$ | 3,477 | |
| Exercisable as of September 30, 2026 | |
| 851,363 | | |
$ | 0.18 | | |
| 7.6 | | |
$ | 2,404 | |
|